Nereid Therapeutics will advance research by Clifford Brangwynne of Princeton University following its launch with a $50m series A round from Apple Tree Partners.

Nereid Therapeutics, a US-based developer of treatments for cancer and neurodegenerative diseases based on research at Princeton University, was launched this week by venture firm Apple Tree Partners with $50m in series A capital.
Nereid will develop therapies targeting biomolecular condensates, a specialised subunit of the cell, using research by scientific founder Clifford Brangwynne, a professor in the Department of Chemical and Biological Engineering at Princeton University and an investigator at the Howard Hughes Medical Institute.
Brangwynne’s work focuses on the biophysical principles at play in organising and forming a healthy cell. Nereid’s drug discovery approach will exploit microscopy and computer vision to quantitatively measure, interrogate and control these processes.
Although biomolecular condensates have long been known about, such a quantitative approach had been out of reach until now. Nereid’s platform could be transformative in a wide range of diseases but will initially focus on certain cancers and neurodegenerative conditions.
Brangwynne will hold a board observer seat and will chair the scientific advisory board.

Thierry Heles

Thierry Heles is the former editor-at-large of Global University Venturing and Global Corporate Venturing, and was the producer and host of the Beyond the Breakthrough podcast until December 2024.